申请人:[en]1GLOBE HEALTH INSTITUTE, NANJING
公开号:WO2024040531A1
公开(公告)日:2024-02-29
The invention provides compositions and linking configurations for an oligonucleotide to be conjugated to a carbohydrate ligand for targeted in vivo delivery of an oligonucleotide. These ligand-conjugated compounds target one or more organs or cell types, e.g., the parenchymal cells of the liver that facilitate endocytic uptake. The compound has structural formula (S-HG1): R206-[A1]a-[A2]b-[A3]c-R205(S-HG1) R205, R206are each independently for each occurrence H, OH, a protecting group for OH, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -OP(M')(M")O-nucleoside, - OP(M')(M")O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, -O- nucleotide, a nucleoside, -OP(M')( M")OR201-OP(M'")(M"")O- oligonucleotide, or an oligonucleotide; M', M", M'" and M"" are each independently for each occurrence O or S; Al, A2 and A3 are each independently for each occurrence selected from (S-1H) or (S-1G).